FDA approves Novartis Piqray® – the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer

EAST HANOVER, N.J., May 24, 2019 /PRNewswire/ — Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib

Source: www.prnewswire.com

The US Food and Drug Administration (FDA) has approved Novartis Advanced Breast-Cancer Treatment Piqray for a type of advanced breast cancer afflicting patients carrying a gene mutation. Piqray in combination with fulvestrant is used for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen.